Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
|
|
H-CYTE, INC. (MDVX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 07/11/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ... |
| 05/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 04/18/2023 |
8-K
| Quarterly results |
| 04/03/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 03/02/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"SECURITIES PURCHASE AGREEMENT",
"H-cyte, Inc. 8.0% CONVERTIBLE MONTH PROMISSORY NOTE Principal Amount: $___,000 U.S. Dollars Issuance Date: February [ ] ___, 2023 FOR VALUE RECEIVED, H-Cyte, Inc., a Nevada corporation hereby promises to pay to the order of _________________________________ the amount set out above as the Principal Amount when due, whether upon the respective Repayment Dates or earlier in accordance with the terms hereof, and to pay interest on any outstanding Principal at the applicable Interest Rate from the date set out above as the Issuance Date until this convertible promissory note has been paid in full. This convertible promissory note, including all promissory notes issued in exchange, transfer or replacement hereof, is referred to as this “Note”. 1. PAYMENTS OF PRINCIPAL . Subject to the conversio...",
"COMMON STOCK PURCHASE WARRANT H-CYTE, INC. Warrant Shares: Initial Exercise Date: Issue Date: THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, __________________ or their assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or the date hereof and on or prior to the close of business on the five year anniversary of the Initial Exercise Date but not thereafter, to subscribe for and purchase from H-Cyte, Inc., a Nevada corporation , up to ________ shares of Common Stock 20% of the shares of Common Stock issuable upon conversion of the Convertible Promissory Note purchased by the Holder in the pursuant to the Securities Purchase Agreement between the Holder and the Company dated __________ ..." |
|
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/28/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/06/2022 |
8-K
| Quarterly results |
| 09/14/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...|
Docs:
|
"RECITALS WHEREAS, the parties intend for H-Cyte to acquire membership interests amounting to 100% of the issued and outstanding membership interests of Jantibody pursuant to Chapter 86 of the Nevada Revised Statutes, as amended from time to time , and on the terms and subject to the conditions set forth in this Agreement; WHEREAS, the Board of Managers of Jantibody has unanimously: determined that it is in the best interests of Jantibody and the Jantibody Members, and declared it advisable, to enter into this Agreement with H-Cyte; approved the execution, delivery, and performance of this Agreement and the consummation of the transactions contemplated hereby, including the Acquisition; and resolved, subject to the terms and conditions set forth in this Agreement, to recommend adoption of t...",
"H-CYTE Completes Acquisition of Jantibody" |
|
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/16/2022 |
8-K
| Quarterly results |
| 06/09/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 05/04/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/05/2022 |
DEF 14C
| Form DEF 14C - Other definitive information statements: |
| 04/04/2022 |
8-K
| Other Events Interactive Data |
| 03/24/2022 |
PRER14C
| Form PRER14C - Information statements: |
| 03/23/2022 |
4
| Lynch Frederick J (10% Owner) has filed a Form 4 on H-CYTE, INC.|
Txns:
| Exercised (in-or-at-the-money) 8,321,785 options to buy
@ $0.014, valued at
$116.5k
Acquired 8,321,785 options to buy
@ $0.014, valued at
$116.5k
|
|
| 03/02/2022 |
8-K
| Quarterly results |
| 02/25/2022 |
4
| FARRIOR J REX III (10% Owner) has filed a Form 4 on H-CYTE, INC.|
Txns:
| Exercised 693,477 options to buy
@ $0.014, valued at
$9.7k
Granted 693,477 options to buy
@ $0.014, valued at
$9.7k
|
|
| 02/25/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/25/2022 |
SC 13D/A
| FWHC HOLDINGS, LLC reports a 67.7% stake in H-Cyte, Inc. |
| 02/25/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/18/2022 |
PRE 14C
| Form PRE 14C - Other preliminary information statements: |
| 02/17/2022 |
3
| Lynch Frederick J (10% Owner) has filed a Form 3 on H-CYTE, INC. |
| 02/16/2022 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 02/15/2022 |
SC 13G
| Lynch Frederick J reports a 11.2% stake in SECTION 240.13d-2 H-Cyte, Inc. |
| 02/15/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/10/2022 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 02/07/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 01/14/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/27/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|